Motor function measure scale, steroid therapy and patients with Duchenne muscular dystrophy

Arquivos de Neuro-Psiquiatria

Elaine C. Da Silva²  Darlene L. Machado²  Maria B. D. Resende²  Renata F. Silva²  Edmar Zanoteli¹  Umbertina C. Reed² 

[1] ,University of São Paulo Medical School Department of NeurologySão Paulo SP ,Brazil

关键词: motor function measure;    muscular dystrophy;    Duchenne;    neuromuscular disease;    medida da função motora;    distrofia muscular de Duchenne;    doença neuromuscular;   

DOI  :  10.1590/S0004-282X2012000300007

来源: SciELO

【 摘 要 】

OBJECTIVE: To assess the evolution of motor function in patients with Duchenne muscular dystrophy (DMD) treated with steroids (prednisolone or deflazacort) through the Motor Function Measure (MFM), which evaluates three dimensions of motor performance (D1, D2, D3). METHODS: Thirty-three patients with DMD (22 ambulant, 6 non-ambulant and 5 who lost the capacity to walk during the period of the study) were assessed using the MFM scale six times over a period of 18 months. RESULTS: All the motor functions remained stable for 14 months in all patients, except D1 for those who lost their walking ability. In ambulant patients, D2 (axial and proximal motor capacities) motor functions improved during six months; an improvement in D3 (distal motor capacity) was noted during the total follow-up. D1 (standing posture and transfers) and total score were useful to predict the loss of the ability to walk. CONCLUSIONS: The use of the MFM in DMD patients confirms the benefits of the steroid treatment for slowing the progression of the disease.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License